CARLSBAD, Calif., April 7, 2014 /PRNewswire/ -- Advanced Biologics announced today that they will be showcasing their most recent peer-reviewed published data at the American Academy of Neurosurgeons (AANS) meeting this week in San Francisco, CA. In the study titled Clinical Evaluation of Allogeneic Growth Factor in Cervical Spine Fusion, a retrospective analysis was conducted of one hundred and forty consecutive patients (228 levels) that had undergone cervical spine fusions using OsteoAMP®. Fusion was assessed by a blinded, independent radiologist at time points of 3 months, 6months, 12months and 18 months. Results demonstrated that eighty percent (80%) of patients had evidence of fusions at 6 months, ninety-eight percent (98%) of patients had evidence of fusions at 12 months, and one hundred percent (100%) of patients had evidence of fusions at 18 months.
"This cervical data along with our other recent study demonstrating superior fusion results over rhBMP-2 continues to further separate the OsteoAMP® technology from other biologic commodities such as DBMs, stem cells and synthetics" stated Scott Cadotte, Vice President of Sales & Marketing. "With so many orthobiologic options available to surgeons, it can be extremely difficult to gauge what claims are real and what is not. Our current advertising message stresses 'No Smoke, No Mirrors' and we believe that this peer-reviewed data further supports that statement."
OsteoAMP® is an award winning allograft-derived growth factor that is a lower-cost alternative to recombinant growth factors, such as rhBMP-2 (Infuse®, Medtronic) and allograft-derived stem cells, such as Osteocel® Plus (Nuvasive) or Trinity® Elite™ (Orthofix). OsteoAMP®'s four distinctive formats (granules, compressible sponges, putty, and structural grafts) provide a distinct advantage by allowing surgeons to tailor deliver the technology according to their needs in surgery.
About Advanced Biologics
Founded in 2009, Advanced Biologics (ABC) is a privately-held company focused on developing innovative and clinically relevant biologic solutions across a wide degree of medical specialties. The OsteoAMP® family of osteoinductive/conductive products is the first line of orthobiologic offerings produced by ABC. ABC has been recognized three times as 'Best New Technology' during the Orthopedics This Week Spine Technology Awards.
SOURCE Advanced Biologics